Arrowhead Pharmaceuticals, Inc. (ARWR) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Arrowhead Pharmaceuticals, Inc. (ARWR) closed at USD 58.37 on 2026-10-14, a change of +47.6 % over the past year, with a market capitalization of USD 8.24B.

Arrowhead Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Arrowhead Pharmaceuticals, Inc. key figures

Previous close

USD 58.37 (2026-10-14)

1-year change

+47.6 %

Market cap

USD 8.24B

Enterprise value

USD 8.05B

P/E ratio (trailing)

-25.55

P/E ratio (forward)

-11.75

EPS (trailing)

-2.29

EPS (forward)

-4.98

PEG ratio

n/a

Price to book

17.74

Revenue growth

171 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.77

Employees

711

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Arrowhead Pharmaceuticals, Inc. and compare it with other stocks.